Table 4.
Gene expression changes induced specifically by the combination of IA2 and ATP-γ-S
| Gene symbol | FC | p valuea | p valueb | Gene name |
|---|---|---|---|---|
| MMP13 | 8.3 | 0.013 | 0.015 | Matrix metallopeptidase 13 (collagenase 3) |
| CXCR4 | 4.9 | 0.006 | 0.001 | Chemokine (C-X-C motif) receptor 4 |
| CXCL9 | 4.8 | 0.013 | 0.029 | Chemokine (C-X-C motif) ligand 9 |
| ADORA2A | 4.2 | 0.005 | 0.000 | Adenosine A2a receptor |
| IFNAR2 | 3.9 | 0.003 | 0.001 | Interferon (alpha, beta and omega) receptor 2 |
| ICOSLG | 3.6 | 0.003 | 0.000 | Inducible T cell costimulator ligand |
| IRAK2 | 3.2 | 0.007 | 0.003 | Interleukin-1 receptor-associated kinase 2 |
| PPP3CC | 3.0 | 0.003 | 0.000 | Protein phosphatase 3, catalytic subunit, gamma isozyme |
| RRAD | 2.8 | 0.015 | 0.005 | Ras-related associated with diabetes |
| EFNA1 | 2.8 | 0.005 | 0.000 | Ephrin-A1 |
| GBP1 | 2.7 | 0.003 | 0.003 | Guanylate binding protein 1, interferon-inducible |
| IL12A | 2.7 | 0.009 | 0.038 | Interleukin 12A |
| FGF12 | 2.7 | 0.048 | 0.045 | Fibroblast growth factor 12 |
| SAA1 | 2.6 | 0.005 | 0.001 | Serum amyloid A1 |
| CD274 | 2.5 | 0.003 | 0.004 | CD274 molecule |
| DGKI | 2.5 | 0.009 | 0.006 | Diacylglycerol kinase, iota |
| NFKB1 | 2.5 | 0.002 | 0.005 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
| SOCS2 | 2.4 | 0.002 | 0.000 | Suppressor of cytokine signalling 2 |
| FOXO1 | 2.4 | 0.003 | 0.037 | Forkhead box O1 |
| SAA2 | 2.4 | 0.003 | 0.001 | Serum amyloid A2 |
| PLA2G4C | 2.3 | 0.007 | 0.031 | Phospholipase A2, group IVC (cytosolic, calcium-independent) |
| IFNGR2 | 2.3 | 0.008 | 0.029 | Interferon gamma receptor 2 (interferon gamma transducer 1) |
| EFNB2 | 2.3 | 0.005 | 0.028 | Ephrin-B2 |
| FOSL1 | 2.2 | 0.007 | 0.017 | FOS-like antigen 1 |
| CSF1 | 2.2 | 0.006 | 0.009 | Colony stimulating factor 1 |
| NFKB2 | 2.2 | 0.011 | 0.019 | Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 |
| RGS17 | 2.2 | 0.010 | 0.011 | Regulator of G-protein signalling 17 |
| THBS1 | 2.1 | 0.005 | 0.000 | Thrombospondin 1 |
| RIPK2 | 2.1 | 0.004 | 0.040 | Receptor-interacting serine-threonine kinase 2 |
| CCL3 | 2.1 | 0.022 | 0.048 | Chemokine (C-C motif) ligand 3 |
| MAP2K3 | 2.1 | 0.009 | 0.041 | Mitogen-activated protein kinase kinase 3 |
| TNFAIP8 | 2.1 | 0.012 | 0.001 | Tumour necrosis factor, alpha-induced protein 8 |
| TLR1 | 2.1 | 0.004 | 0.001 | Toll-like receptor 1 |
| TFAP2C | 2.1 | 0.006 | 0.027 | Transcription factor AP-2 gamma (activating enhancer binding protein 2 γ) |
| CEBPB | 2.0 | 0.005 | 0.017 | CCAAT/enhancer binding protein (C/EBP), beta |
| IL28B | 2.0 | 0.016 | 0.041 | Interleukin 28B (interferon, lambda 3) |
| NR2F1 | −2.0 | 0.002 | 0.017 | Nuclear receptor subfamily 2, group F, member 1 |
| MAP2K6 | −2.0 | 0.022 | 0.039 | Mitogen-activated protein kinase kinase 6 |
| PPARGC1A | −2.1 | 0.011 | 0.041 | Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
| GLI2 | −2.1 | 0.046 | 0.049 | GLI family zinc finger 2 |
| ID2 | −2.2 | 0.004 | 0.041 | Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein |
| CDH6 | −2.4 | 0.010 | 0.005 | Cadherin 6, type 2, K-cadherin (foetal kidney) |
| IGSF5 | −2.5 | 0.004 | 0.003 | Immunoglobulin superfamily, member 5 |
| PPP1R3C | −2.6 | 0.005 | 0.003 | Protein phosphatase 1, regulatory (inhibitor) subunit 3C |
| CAT | −2.8 | 0.030 | 0.034 | Catalase |
| NR3C2 | −2.9 | 0.037 | 0.041 | Nuclear receptor subfamily 3, group C, member 2 |
| GPER | −3.0 | 0.003 | 0.000 | G protein-coupled oestrogen receptor 1 |
| ARHGAP20 | −3.1 | 0.014 | 0.046 | Rho GTPase activating protein 20 |
| OXR1 | −3.2 | 0.031 | 0.044 | Oxidation resistance 1 |
| EPHA4 | −3.2 | 0.007 | 0.001 | EPH receptor A4 |
| CTGF | −3.4 | 0.007 | 0.001 | Connective tissue growth factor |
| CCR6 | −4.2 | 0.012 | 0.021 | Chemokine (C-C motif) receptor 6 |
| SLC17A1 | −4.3 | 0.007 | 0.008 | Solute carrier family 17 (sodium phosphate), member 1 |
| CSRNP3 | −5.2 | 0.018 | 0.009 | Cysteine-serine-rich nuclear protein 3 |
FC fold change vs. unstimulated controls, p Benjamini-Yekutieli multiple testing corrected p value
aSignificance vs. unstimulated controls (n = 4)
bSignificance vs. IA2 or ATP-γ-S stimulation (n = 4)